Buy or sell Humacyte stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Humacyte Stock
Biotechnology
About Humacyte Stock
Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
Investors
Access Industries
Gett, WeLab, IronSource, Humacyte, Deezer, TangoMe, Selina, Sentient Technologies, DigitalOcean
Bangkok bank
California Institute for Regenerative Medicine
Pacific Eagle Asset Management
Funding History
| November 2009 | $7.0M |
|---|---|
| September 2010 | $12.0M |
| January 2015 | $49.8M |
| October 2015 | $150M |
| August 2016 | $10.0M |
| September 2017 | $14.1M |
| March 2018 | $75.0M |
| June 2018 | $150M |
Management
Chief Executive Officer
Jeffrey Lawson
Co-Founder & Executive Vice President, Strategic Business Operations
Julianna Blum
Chief Financial Officer
Douglas Blankenship
Press
Business Wire - Mar, 27 2020
Business Wire - Mar, 2 2020
Business Wire - Apr, 8 2019
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Humacyte or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
